AI Terminal
aap Implantate AG
Earnings Release • Apr 2, 2019
10_rns_2019-04-02_048670fe-6997-4494-bb86-0b3a543a4b0c.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Corporate | 2 April 2019 12:22
aap: Good start to the year with 25% sales growth in Q1/2019; double-digit growth rates in all regions
DGAP-News: aap Implantate AG / Key word(s): Preliminary Results/Development of Sales
02.04.2019 / 12:22
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (“ aap “) made a successful start in financial year 2019 with significant sales growth. According to preliminary figures, aap increased sales by 25% year on year in the first three months of the current year to EUR 3.5 million (Q1/2018: EUR 2.8 million). Thereby the company realized a value above the forecast provided in January of EUR 2.0 million to EUR 3.0 million.
Sales
| In KEUR | Q1/2019 | Q1/2018 | Change on year |
| Trauma Germany North America North America distributors North America global partners International (without North America) Europe (without Germany) BRICS states Total key markets Rest |
3,428 749 626 610 16 2,053 654 821 1,475 578 |
2,797 656 531 513 18 1,610 502 738 1,240 370 |
+23% +14% +18% +19% -11% +28% +30% +11% +19% +56% |
| Other | +53 | -15 | >+100% |
| Sales | 3,481 | 2,782 | +25% |
All regions contributed with double-digit growth rates to the realised sales increase. aap was able to maintain the last financial year’s momentum in Germany (+14%) and in international business (+28%) in the first quarter of 2019 as well and thereby recorded sustainable growth. In North America sales development was stabilised (+18%). This shows that the measures initiated in financial year 2018 are starting to have an effect.
Against the background of this development the Management Board now anticipates EBITDA of EUR -1.2 million to EUR -0.9 million (previous: EUR -1.8 million to EUR -1.2 million) for the first quarter of 2019.
The figures contained in this press release are preliminary as of 31 March 2019, which are subject to change until final publication. aap plans to publish the final figures for the first quarter of 2019 on 13 May 2019.
*——————————————————————————————————————————————-
aap* Implantate AG (ISIN DE0005066609) – Prime Standard/Regulated Market – All German stock markets –
About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven’t yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG’s stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company’s investor relations app from the Apple’s App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap ‘s public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
Contact:
aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; D-12099 Berlin Tel.: +49/30/750 19 – 134; Fax.: +49/30/750 19 – 290; [email protected]
02.04.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | aap Implantate AG |
| Lorenzweg 5 | |
| 12099 Berlin | |
| Germany | |
| Phone: | +49 (0) 30 75 01 90 |
| Fax: | +49 (0) 30 75 01 91 11 |
| E-mail: | [email protected] |
| Internet: | www.aap.de |
| ISIN: | DE0005066609 |
| WKN: | 506660 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 794693 |
| End of News | DGAP News Service |